Table 2.
Baseline characteristics of patients from the four cohorts, ordered by mean utility score
| BROSG n = 466 |
BSRBR control n = 188 |
STIVEA n = 182 |
BSRBR n = 223 |
|
|---|---|---|---|---|
| Age (years) | 60.6 (11.2) | 60.2 (11.7) | 55.5 (15.0) | 57.9 (12.2) |
| Sex, female, n (%) | 317 (68%) | 142 (76%) | 182 (69%) | 168 (75%) |
| Disease duration (years) | 12.5 (6.7) | 11.8 (10.9) | 0.15 (0.05) | 13.4 (11.5) |
| EQ-5D | 0.59 (0.22) | 0.55 (0.27) | 0.46 (0.31) | 0.34 (0.33) |
| SF-6D | 0.64 (0.13) | 0.59 (0.12) | 0.56 (0.13) | 0.50 (0.09) |
| EQ-VAS | 64.8 (18.1) | 58.3 (18.7) | 58.8 (21.3) | 48.1 (21.1) |
| HAQa | 1.28 (0.70) | 1.38 (0.75) | 1.23 (0.69) | 1.92 (0.60) |
| DAS28a | 4.04 (1.26) | 4.99 (1.09) | 5.39 (1.10) | 6.41 (1.03) |
| 28 Tender joint counta | 5.1 (5.9) | 7.6 (6.0) | 10.6 (6.6) | 15.3 (7.2) |
| 28 Swollen joint counta | 4.2 (4.2) | 5.0 (4.5) | 8.9 (5.1) | 10.3 (6.4) |
| ESR (mm/h)a | 23.8 (22.9) | 35.1 (24.1) | 36.6 (26.5) | 42.7 (27.8) |
Numbers are mean (s.d.) unless otherwise stated
EQ-5D EuroQol-5D, SF-6D short form-6D, EQ-VAS EuroQol visual analogue scale, STIVEA steroids in very early arthritis, BROSG British Rheumatoid Outcome Study Group, BSRBR British Society for Rheumatology Biologics Register, HAQ Health Assessment Questionnaire, DAS28 Disease Activity Score based on 28 swollen joint counts, ESR = erythrocyte sedimentation rate, s.d., standard deviation
aHigher values denote more severe disease